vs
Side-by-side financial comparison of ECB Bancorp, Inc. (ECBK) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $9.5M, roughly 2.0× ECB Bancorp, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs 27.3%, a 38.4% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 33.8%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 23.8%).
ECB Bancorp, Inc. (MD) is a US-based bank holding company. It offers a full suite of retail and commercial banking products including deposit accounts, consumer loans, commercial financing and wealth management solutions, primarily serving individuals and small-to-mid enterprises across local markets in Maryland.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
ECBK vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.5M | $18.6M |
| Net Profit | $2.6M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 36.7% | 56.3% |
| Net Margin | 27.3% | 65.7% |
| Revenue YoY | 33.8% | 1808.5% |
| Net Profit YoY | 79.5% | 376.5% |
| EPS (diluted) | $0.32 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.5M | $18.6M | ||
| Q3 25 | $8.8M | $334.0K | ||
| Q2 25 | $8.0M | $1.4M | ||
| Q1 25 | $6.9M | $257.0K | ||
| Q4 24 | $7.1M | $977.0K | ||
| Q3 24 | $6.6M | $660.0K | ||
| Q2 24 | $6.3M | $736.0K | ||
| Q1 24 | $6.2M | $1.4M |
| Q4 25 | $2.6M | $12.3M | ||
| Q3 25 | $2.4M | $-8.6M | ||
| Q2 25 | $1.4M | $-6.9M | ||
| Q1 25 | $1.3M | $-5.4M | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.1M | $-2.8M | ||
| Q2 24 | $791.0K | $-14.5M | ||
| Q1 24 | $621.0K | $411.0K |
| Q4 25 | 36.7% | 56.3% | ||
| Q3 25 | 37.0% | -2516.5% | ||
| Q2 25 | 23.9% | -701.0% | ||
| Q1 25 | 24.9% | -3350.2% | ||
| Q4 24 | 27.3% | — | ||
| Q3 24 | 23.3% | -1563.6% | ||
| Q2 24 | 16.9% | -1255.0% | ||
| Q1 24 | 13.4% | -692.5% |
| Q4 25 | 27.3% | 65.7% | ||
| Q3 25 | 27.7% | -2572.2% | ||
| Q2 25 | 18.0% | -504.8% | ||
| Q1 25 | 18.7% | -2097.7% | ||
| Q4 24 | 20.3% | — | ||
| Q3 24 | 17.2% | -425.5% | ||
| Q2 24 | 12.6% | -1964.4% | ||
| Q1 24 | 10.0% | 29.9% |
| Q4 25 | $0.32 | $0.25 | ||
| Q3 25 | $0.29 | $-0.17 | ||
| Q2 25 | $0.17 | $-0.14 | ||
| Q1 25 | $0.16 | $-0.11 | ||
| Q4 24 | $0.18 | — | ||
| Q3 24 | $0.14 | $-0.06 | ||
| Q2 24 | $0.09 | $-0.30 | ||
| Q1 24 | $0.07 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $82.8M | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $171.9M | $49.4M |
| Total Assets | $1.6B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $82.8M | $40.0M | ||
| Q3 25 | $201.9M | $37.9M | ||
| Q2 25 | $191.0M | $44.8M | ||
| Q1 25 | $143.7M | $40.6M | ||
| Q4 24 | $309.4M | $59.3M | ||
| Q3 24 | $114.8M | $68.8M | ||
| Q2 24 | $108.7M | $73.0M | ||
| Q1 24 | $109.8M | $80.2M |
| Q4 25 | $171.9M | $49.4M | ||
| Q3 25 | $169.3M | $36.4M | ||
| Q2 25 | $168.3M | $44.5M | ||
| Q1 25 | $168.6M | $50.5M | ||
| Q4 24 | $168.3M | $55.1M | ||
| Q3 24 | $166.0M | $58.5M | ||
| Q2 24 | $166.5M | $60.4M | ||
| Q1 24 | $165.8M | $74.1M |
| Q4 25 | $1.6B | $59.0M | ||
| Q3 25 | $1.6B | $51.1M | ||
| Q2 25 | $1.5B | $60.7M | ||
| Q1 25 | $1.5B | $67.9M | ||
| Q4 24 | $1.4B | $90.6M | ||
| Q3 24 | $1.4B | $99.0M | ||
| Q2 24 | $1.3B | $107.8M | ||
| Q1 24 | $1.3B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.2M | $18.4M |
| Free Cash FlowOCF − Capex | $9.0M | — |
| FCF MarginFCF / Revenue | 94.7% | — |
| Capex IntensityCapex / Revenue | 2.2% | — |
| Cash ConversionOCF / Net Profit | 3.55× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $14.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.2M | $18.4M | ||
| Q3 25 | $4.0M | $-8.7M | ||
| Q2 25 | $1.9M | $-7.5M | ||
| Q1 25 | $-631.0K | $-7.5M | ||
| Q4 24 | $6.2M | $-24.0M | ||
| Q3 24 | $861.0K | $765.0K | ||
| Q2 24 | $1.4M | $-10.9M | ||
| Q1 24 | $-429.0K | $-4.0M |
| Q4 25 | $9.0M | — | ||
| Q3 25 | $4.0M | — | ||
| Q2 25 | $1.8M | — | ||
| Q1 25 | $-649.0K | — | ||
| Q4 24 | $6.2M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $-449.0K | — |
| Q4 25 | 94.7% | — | ||
| Q3 25 | 44.9% | — | ||
| Q2 25 | 23.0% | — | ||
| Q1 25 | -9.4% | — | ||
| Q4 24 | 86.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 21.4% | — | ||
| Q1 24 | -7.2% | — |
| Q4 25 | 2.2% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.6% | — | ||
| Q1 25 | 0.3% | — | ||
| Q4 24 | 0.8% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.6% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | 3.55× | 1.50× | ||
| Q3 25 | 1.65× | — | ||
| Q2 25 | 1.32× | — | ||
| Q1 25 | -0.49× | — | ||
| Q4 24 | 4.31× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | -0.69× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ECBK
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
